A Randomized, Single-Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of GSK2878175 in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs GSK 2878175 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline
- 06 Feb 2014 Status changed to completed as reported by ClincalTrials.gov record.
- 24 Jun 2013 New trial record
- 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.